Tumour Trace is excited to be awarded a tranche of European Commission (EC) funding through the latest Horizon 2020 programme. A unique quality of the Tumour Trace device is its patented technology, Opto-Magnetic Imaging Spectroscopy (OMIS), which is able to accurately identify cancerous cells objectively (see case studies).

Our technology relies on assessing the spectra of covalent bonds and free water molecules in a cellular and extracellular space which can be examined as a biomarker to determine whether the cell is abnormal.[i] This innovative technology provides an objective methodology for cancer detection and offers a step change in accuracy, costs and speed of screening.

The funding will enable us to conduct more widespread, larger sample size clinical trials using a number of CE marked devices (Class 1 in vitro medical device) being manufactured in partnership with The Manufacturing Technology Centre. This moves us closer to our vision of providing early cancer screening for everyone, everywhere.

Results from our initial clinical studies conducted over period 2011-2015, indicate our method shows promising results. Further peer approved and National Institute for Health Research (NIHR) registered and published research trials, conducted using a greater volume of specimen samples could see us moving closer to providing a rapid, highly accurate diagnostic device for cervical cancer which could reduce screening costs by up to 75%, offering potential savings of circa €648 million across EU screening programmes.

[i]Abramczyk H, Brozek-Pluska B, Krzesniak M, Kopec M and Morawiec-Sztandera A. (2014). The Cellular Environment of Cancerous Human Tissue. Interfacial and Dangling Water as a “Hydration Fingerprint”. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 129, 609-623.